Drug Trial Radar · NCT00002823
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Mar 28, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,300
Planned (sponsor's estimate)
Start
Feb 1995
Primary completion
Jan 2001
Sponsor
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 11, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy given after surgery is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy following surgery with that of surgery alone in treating patients who have stage I, stage II, or stage IIIA non-small cell lung cancer.
Conditions
- Lung Cancer
Interventions
cisplatinDrug
etoposideDrug
vinblastine sulfateDrug
vindesineDrug
vinorelbine tartrateDrug
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
123 sites in 29 countries. Site status is shown where the registry gives one.
Comprehensive Cancer Center at JFK Medical Center
Atlantis, Florida
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Getlac
Buenos Aires, Argentina
South Eastern Sydney Area Health Service
Randwick, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Peter MacCallum Cancer Institute
East Melbourne, Victoria, Australia
Western Hospital
Melbourne, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
AKH Vienna
Vienna, Austria
A.Z. St. Jan
Bruges, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
U.Z. Gasthuisberg
Leuven, Belgium
AZ Zusters Van Barmhartigheid
Ronse, Belgium
Sint Elizabeth Ziekenhuis
Zottegem, Belgium
University of Clementino Fraga
Rio de Janeiro, Brazil
Instituto Nacional de Cancer
Rio de Janeiro, Rio de Janeiro, Brazil
Porto Alegre Hospital
Porto Alegre, Rio Grande do Sul, Brazil
Hospital A.C. Camargo
São Paulo, São Paulo, Brazil
Clinica Las Nieves
Santiago, Chile
Hospital Militar Central
Bogotá, Colombia
Instituto Nacional De Cancerologia
Bogotá, Colombia
Chest Disease Clinic, Charles University
Prague (Praha), Czechia
National Cancer Institute of Egypt
Cairo, Egypt
Institute for Lung Diseases
Belgrade, Federal Republic of Yugoslavia
Centre Hospitalier Regional et Universitaire d'Angers
Angers, France
Centre Paul Papin
Angers, France
C.H. Armentieres
Armentières, France
Centre Hospital General Robert Ballanger
Aulnay-sous-Bois, France
C.H. Henri Mondor
Aurillac, France
Clinique Hauts De Seine Bagneux
Bagneux, France
C.H.G. Beauvais
Beauvais, France
Hopital Avicenne
Bobigny, France
C.M.C. Du Cedre
Bois Guillaume (Rouen), France
Institut Bergonie
Bordeaux, France
CHU de Caen
Caen, France
Centre Regional Francois Baclesse
Caen, France
Centre Du Meridien
Cannes, France
Hopital Fontenoy
Chartres, France
Hopital Antoine Beclere
Clamart, France
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.